Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Rhea-AI Summary
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company focused on its POZ Platform™ drug optimization technology, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Steve Ledger will deliver a presentation on September 8, 2025, at 9:30 a.m. ET in New York.
The presentation will be available via live webcast for registered attendees, with an on-demand replay accessible for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SER gained 1.77%, reflecting a mild positive market reaction. Argus tracked a trough of -20.6% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $956K to the company's valuation, bringing the market cap to $55M at that time.
Data tracked by StockTitan Argus on the day of publication.
HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York, NY on September 8, 2025, at 9:30 a.m. ET.
A live webcast of the presentation will be accessible to registered attendees at this link. An archived replay will be available on-demand for 90 days following the event.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://www.serinatx.com/.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs, or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina’s Annual Report on Form 10-K, and Serina’s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
FAQ
When is Serina Therapeutics (SER) presenting at the H.C. Wainwright Conference?
Who will be presenting for Serina Therapeutics at the H.C. Wainwright Conference?
How can investors access Serina Therapeutics' H.C. Wainwright Conference presentation?
What is Serina Therapeutics' main technology focus?
